The DOD Neurofibromatosis Research Program awards grant to collaborative project between James Walker’s Lab at MGH and iNFixion Bioscience

A three-year grant through the DOD Neurofibromatosis Research Program (NFRP) has been awarded to Dr. James Walker’s lab at Massachusetts General Hospital (MGH), with iNFixion Bioscience as a sub-awardee, to develop and validate a lentiviral CRISPRa/Cas9 tool designed to enhance NF1 protein expression. The Walker Lab will design the CRISPRa/Cas9 compounds for testing, while iNFixion will evaluate their efficacy in both cellular and rodent models. This research will not only provide a tool to evaluate iNFixion’s NF1 haploinsufficiency correction therapy (NF1-HCT), but could also serve as the foundation for a potential NF1 therapeutic.